283 related articles for article (PubMed ID: 21942912)
1. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.
Ho M
BioDrugs; 2011 Oct; 25(5):275-84. PubMed ID: 21942912
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3: a new target for cancer immunotherapy.
Ho M; Kim H
Eur J Cancer; 2011 Feb; 47(3):333-8. PubMed ID: 21112773
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma.
Allegretta M; Filmus J
Anticancer Agents Med Chem; 2011 Jul; 11(6):543-8. PubMed ID: 21554204
[TBL] [Abstract][Full Text] [Related]
4. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
5. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
Pang N; Shi J; Qin L; Chen A; Tang Y; Yang H; Huang Y; Wu Q; Li X; He B; Li T; Liang B; Zhang J; Cao B; Liu M; Feng Y; Ye X; Chen X; Wang L; Tian Y; Li H; Li J; Hu H; He J; Hu Y; Zhi C; Tang Z; Gong Y; Xu F; Xu L; Fan W; Zhao M; Chen D; Lian H; Yang L; Li P; Zhang Z
J Hematol Oncol; 2021 Jul; 14(1):118. PubMed ID: 34325726
[TBL] [Abstract][Full Text] [Related]
6. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
Phung Y; Gao W; Man YG; Nagata S; Ho M
MAbs; 2012; 4(5):592-9. PubMed ID: 22820551
[TBL] [Abstract][Full Text] [Related]
7. The role of mesothelin in tumor progression and targeted therapy.
Tang Z; Qian M; Ho M
Anticancer Agents Med Chem; 2013 Feb; 13(2):276-80. PubMed ID: 22721387
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances.
Li D; Lin S; Hong J; Ho M
Adv Cancer Res; 2022; 156():415-449. PubMed ID: 35961708
[TBL] [Abstract][Full Text] [Related]
9. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
10. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
11. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
Nishimura Y; Nakatsura T; Senju S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy.
Hanaoka H; Nagaya T; Sato K; Nakamura Y; Watanabe R; Harada T; Gao W; Feng M; Phung Y; Kim I; Paik CH; Choyke PL; Ho M; Kobayashi H
Mol Pharm; 2015 Jun; 12(6):2151-7. PubMed ID: 25955255
[TBL] [Abstract][Full Text] [Related]
15. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
[TBL] [Abstract][Full Text] [Related]
16. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis.
Yu J; Ma Q; Zhang B; Ma R; Xu X; Li M; Xu W; Li M
Sci China Life Sci; 2013 Mar; 56(3):234-9. PubMed ID: 23526389
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
[TBL] [Abstract][Full Text] [Related]
18. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
[TBL] [Abstract][Full Text] [Related]
19. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
[TBL] [Abstract][Full Text] [Related]
20.
Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
